Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI110 Plus Sintilimab in Neoadjuvant and Adjuvant NSCLC
NCT05088967Phase 1Terminated
- Sponsor
- Innovent Biologics
- Start
- Dec 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibi110 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Pathologic Complete Response, Incidence of Adverse Events and 5 more. Started Dec 2021; status: terminated.
02
Drugs
ibi110
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05088967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088967.